Tangbi (prescription)
Phase 1Small molecule
Tangbi (prescription) is one of 20 small molecule programs targeting Polyneuropathy. It is currently in Phase 1.
1
Indications
1
Total Trials
0
Active Trials
19
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
25 competitors in Polyneuropathy
#DrugCompanyPhaseTrials
1Keppra
UCBApproved
Lexapro
AbbVieApproved
Tofranil
SanofiApproved
Vyndaqel
KK-Group Alpha, Inc., a wholly owned subsidiary of Zentalis Pharmaceuticals, Inc.
Approved
Lyrica
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Approved
Dilantin
VViatris Specialty LLC
Approved
Rituxan
RochePhase 3
Wainua (autoinjector)
AstraZenecaPhase 3
Fx-1006a
PfizerPhase 3
Lipoic Acid
NNovaMed Pharmaceuticals Inc.
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Polyneuropathy1 trial
The Multi-Centric Clinical Study of Chinese Medicine Intervention on Diabetes Distal Symmetric Polyneuropathy.
Unknown status·GGuang'anmen Hospital of China Academy of Chinese Medical Sciences·Phase 1·NCT03010241·188 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Tangbi (prescription). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details